Dual Hormone Therapy Around Surgery Boosts Outcomes in High-Risk Prostate Cancer
A phase 3 trial finds combining two hormone therapies before and after prostate surgery outperforms single hormone therapy in high-risk cases.
Summary
A major clinical trial called PROTEUS has found that men with high-risk, early-stage prostate cancer may benefit from a new treatment approach: combining two hormone therapies both before and after surgical removal of the prostate. This outperformed the current standard of using just one hormone therapy around surgery. The findings, published alongside an editorial in the New England Journal of Medicine, have leading oncologists suggesting this could become a new standard of care. Currently, high-risk prostate cancer patients choose between surgery alone or radiation paired with hormone therapy. This trial introduces a third option that may improve outcomes for those who prefer surgery, potentially reducing the risk of cancer returning after the procedure.
Detailed Summary
Prostate cancer remains one of the most common cancers affecting men, and for those with high-risk disease that hasn't yet spread, treatment decisions carry significant weight. The PROTEUS phase 3 clinical trial has now produced results that many oncologists believe could reshape how high-risk, localized prostate cancer is treated surgically.
The trial compared two hormone therapy drugs used together versus one hormone therapy drug alone, both administered before and after prostate removal surgery. The combination approach proved superior, showing meaningfully better outcomes for patients in the high-risk, early-stage category. These results were considered significant enough to prompt an editorial in the prestigious New England Journal of Medicine, where one expert called it a 'watershed moment' in prostate cancer treatment.
Currently, patients with this cancer profile face two standard options: surgical removal of the prostate, or a combination of radiation and hormone therapy. Surgery alone has historically lacked a well-established hormone therapy protocol to accompany it. The PROTEUS findings suggest that adding dual hormone therapy as a perioperative strategy — meaning around the time of surgery — could substantially improve the surgical treatment pathway.
For health-conscious men and their physicians, this is practically meaningful. It suggests that if surgery is strongly preferred, patients may no longer need to feel they are choosing a less optimized path. The addition of hormone therapy on both sides of surgery could reduce recurrence risk and potentially extend disease-free survival.
However, caveats remain. The full trial data and long-term survival outcomes are behind a paywall, limiting complete public assessment. Hormone therapy carries its own side effects, including effects on bone density, cardiovascular health, and metabolic function. Patients should discuss the full risk-benefit profile with a specialist before pursuing this approach.
Key Findings
- Combining two hormone therapies before and after prostate surgery outperformed single hormone therapy in high-risk cases.
- PROTEUS trial results may establish a new third standard-of-care option for high-risk, localized prostate cancer.
- Leading oncologists, including a NEJM editorial author, called the findings a 'watershed moment' in prostate cancer.
- Patients preferring surgery may now have a more optimized perioperative hormone protocol to reduce recurrence risk.
- High-risk, early-stage prostate cancer patients who haven't yet metastasized are the target population for this approach.
Methodology
This is a news report from STAT News summarizing results of the PROTEUS phase 3 randomized clinical trial, a high-evidence study design. The findings were published or editorialized in the New England Journal of Medicine, a top-tier peer-reviewed journal. Full article content is behind a paywall, limiting direct access to trial methodology and outcome data.
Study Limitations
The article is truncated behind a STAT+ paywall, so primary outcome data, hazard ratios, follow-up duration, and safety profiles cannot be fully evaluated here. Long-term overall survival benefits have not been confirmed and require further follow-up. Readers should consult the full NEJM publication and a genitourinary oncologist before drawing clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.